Hostname: page-component-76fb5796d-5g6vh Total loading time: 0 Render date: 2024-04-27T23:02:48.569Z Has data issue: false hasContentIssue false
  • English
  • Français

Salbutamol inhaler abuse and psychosis

Published online by Cambridge University Press:  13 June 2014

Paul A Cotter
Paul A Cotter*
Affiliation:
Section of Metabolic Studies, Institute of Psychiatry, Denmark Hill, London SE5 8AF, England
Get access Rights & Permissions [Opens in a new window]

Abstract

A case is described in which a man with asthma and a history of alcohol dependence presented with a paranoid psychosis refractory to standard neuroleptic treatment. Symptomatic improvement was achieved when abuse of salbutamol (Ventolin®) metered dose inhaler was discovered and an alternative β2-agonist delivery system prescribed. A contribution by salbutamol to the psychosis is proposed. It is suggested that increased awareness regarding psychiatric morbidity is needed when metered dose salbutamol inhalers are prescribed.

Keywords

Salbutamolβ2-agonistsMetered dose inhalersAbusePsychosesAffective disorders
Type
Case Reports
Information
Irish Journal of Psychological Medicine , Volume 14 , Issue 2 , June 1997 , pp. 76 - 77
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Pratt, HFAbuse of salbutamol inhalers in young people. Clin Allergy 1982; 12: 203–8.CrossRefGoogle ScholarPubMed
2.Brennan, PO. Inhaled salbutamol: a new form of drug abuse? Lancet 1983; ii: 1030–1.CrossRefGoogle Scholar
3.Thompson, PJ, Dhillon, P, Cole, P. Addiction to aerosol treatment: the asthmatic alternative to glue sniffing. BMJ 1983; 287: 1515–6.CrossRefGoogle ScholarPubMed
4.Brennan, PO. Addiction to aerosol treatment. BMJ 1983; 287: 1877.Google Scholar
5.Raine, JM. Addiction to aerosol treatment. BMJ 1984; 288: 241.CrossRefGoogle ScholarPubMed
6.O'Callaghan, C, Milner, AD. Aerosol treatment abuse. Arch Dis Child 1988; 63: 70.CrossRefGoogle ScholarPubMed
7.Wickramasinghe, H, Liebeschuetz, HJ. Addiction to aerosol treatment. BMJ 1983; 287: 1877.CrossRefGoogle Scholar
8.Gluckman, L. Ventolin psychosis. N Z Med J 1974; 80: 411.Google ScholarPubMed
9.Edwards, JG, Holgate, ST. Dependency upon salbutamol inhalers. Br J Psychiatry 1979; 134: 624–6.CrossRefGoogle ScholarPubMed
10.Prasher, VP, Corbett, JA. Aerosol addiction. Br J Psychiatry 1990; 157: 922–4.CrossRefGoogle ScholarPubMed
11.Slessor, IM. Addiction to aerosol treatment. BMJ 1984; 288: 485.CrossRefGoogle ScholarPubMed
12.Bass, M. Sudden sniffling death. JAMA 1970; 212: 2075–9.CrossRefGoogle Scholar
13.Kjelleman, B. Case report: an asthmatic child with a very high consumption of Ventoline respirator solution. Scand J Resp Dis 1977; (suppl 101): 119–21.Google Scholar
14.Waldmeier, PC. Stimulation of central serotonin turnover by beta-adrenoceptor agonists. Naunyn-Schmiedebergs Arch Pharmacol 1981; 317: 115–9.CrossRefGoogle ScholarPubMed
15.Caccia, S, Fong, MH. Kinetics and distribution of the, β-adrenergic agonist salbutamol in rat brain. J Pharm Pharmacol 1983; 36: 200–1.CrossRefGoogle Scholar
16.Frances, H, Peuch, AJ, Chermat, R, Simon, P. Are psycho-pharmacological effects of β-adrenergic stimulants central or peripheral? Pharmacol Res Commun 1979; 11: 273–8.CrossRefGoogle ScholarPubMed
17.Mogilnicka, E. The effects of acute and repeated treatment with salbutamol, a beta-adrenoceptor agonist, on clonidine-induced hypoactivity in rats. J Neural Transm Gen Sect 1982; 53: 117–26.CrossRefGoogle ScholarPubMed
18.Borsini, F, Bendotti, C, Thurlby, P, Samanin, R. Evidence that systematically administered salbutamol reduces food intake in rats by acting on central beta-adrenergic sites. Life Sci 1982; 30: 905–11.CrossRefGoogle Scholar
19.Cowen, PJ, Grahame-Smith, DG, Green, AR, Heal, DJ. Adrenoceptors agonists enhance 5-hydroxytryptramine-mediated behavioural responses. Br J Pharmacol 1982; 76: 265–70.CrossRefGoogle ScholarPubMed
20.Frances, H, Simon, P. The effect of a β-agonist on behaviour mediated by 5-HT1A and 5-HT1B receptors. Biol Psychiatry 1986; 21: 1072–5.CrossRefGoogle Scholar
21.Avorn, J, Everitt, DE, Weiss, S. Increased antidepressant use in patients prescribed, β-blockers. JAMA 1986; 255: 357–60.CrossRefGoogle ScholarPubMed
22.Widlocher, D, Lecrubier, Y, Jouvent, R, Puech, AJ, Simon, P. Antidepressant effect of salbutamol. Lancet 1977; ii: 767–8.CrossRefGoogle Scholar
23.Simon, P, Lecrubier, Y, Jouvent, R, Puech, AJ, Allilaire, JF, Widlocher, D. Experimental and clinical evidence of the antidepressant effect of a beta-adrenergic stimulant. Psychol Med 1978; 8: 335–8.CrossRefGoogle ScholarPubMed
24.Lecrubier, Y, Puech, AJ, Jouvent, R, Simon, P, Widlocher, D. A beta-adrenergic stimulant (salbutamol) versus clomipramine in depression: a controlled study. Br J Psychiatry 1980; 136: 354–8.CrossRefGoogle ScholarPubMed
25.Lerer, B, Ebstein, RP, Belmaker, RH. Subsensitivity of human β-adrenergic adenylate cyclase after salbutamol treatment of depression. Psychopharmacology 1981; 75: 169–72.CrossRefGoogle ScholarPubMed
26.Simon, P, Lecrubier, Y, Jouvent, R, Puech, A, Widlocher, D. β-receptor stimulation in the treatment of depression. Adv Biochem Psychopharmacol 1984; 39: 293–300.Google ScholarPubMed
27.Edwards, DJ, Sorisio, DA, Knopf, S. Effects of the β2-adrenoceptor agonist clenbuterol on tyrosine and tryptophan in plasma and brain of the rat. Biochem Pharmacol 1989; 38: 295–301.CrossRefGoogle Scholar
28.Finnegan, KT, Terwilliger, MM, Berger, PA, Hollister, LE, Csernansky, JG. A comparison of the neurochemical and behavioural effects of clenbuterol and desipramine. Eur J Pharmacol 1987; 134: 131–6.CrossRefGoogle ScholarPubMed
29.Jacquot, M, Bottari, R. Manic episode precipitated by oral intake of salbutamol. L'Encephale 1981; 7: 45–9.Google Scholar
30.Ray, I, Evans, CJ. Paranoid psychosis with Ventolin (salbutamol tablets b.p.) Can Psych Ass J 1978; 23(60): 427.Google ScholarPubMed
31.Whitehouse, AM, Novosel, S. Salbutamol psychosis. Biol Psychiatry 1989; 26: 631–3.CrossRefGoogle ScholarPubMed
32.Khanna, PB, Davies, R. Hallucinations associated with administration of salbutamol via nebuliser. Br Med J 1986; 292: 1430.Google Scholar
33.Feline, A, Jouvent, R. Manifestations psychosensorieuse observees chez des psychotiques soumises a des medications β-mimetriques. L'Encephale 1977; 3: 149–58.Google Scholar